OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
26
Results
Show all
Save search
Copy query
Show results for
Unknown
(26)
Publication Date
Release Date
2021
(8)
2023
(6)
2022
(5)
2025
(3)
2024
(1)
2020
(1)
2017
(1)
2016
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.
Not available
S-EPMC5568774
|
biostudies-literature
Cite
Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer.
Not available
S-EPMC12641601
|
biostudies-literature
Cite
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC10326520
|
biostudies-literature
Cite
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Not available
S-EPMC9857594
|
biostudies-literature
Cite
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Not available
S-EPMC8274471
|
biostudies-literature
Cite
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8941448
|
biostudies-literature
Cite
Design, recruitment and baseline characteristics of the LENS trial.
Not available
S-EPMC7617915
|
biostudies-literature
Cite
Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.
Not available
S-EPMC7617897
|
biostudies-literature
Cite
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.
Not available
S-EPMC8908850
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets